Gilead Sciences Inc at TD Cowen Health Care Conference Transcript

Mar 05, 2024 / 05:50PM GMT
Tyler Martin Van Buren - TD Cowen, Research Division - MD & Senior Equity Research Analyst

Welcome and good afternoon everyone. Welcome again to TD Cowen's 44th Annual Healthcare Conference, Day 2. My name is Tyler Van Buren, Senior Biotech Analyst here. For our next session, very pleased to have a fireside chat with Gilead. And from Gilead, it's my pleasure to introduce Andy Dickinson, Chief Financial Officer. Andy, thank you very much for being here.

Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO

Thank you, for us all to be here again. Thanks for having us.

Tyler Martin Van Buren - TD Cowen, Research Division - MD & Senior Equity Research Analyst

So before I get started, if you guys have questions, chime in or raise your hand and we'll do our best to get them asked. So to open, Andy, I wanted to start with Gilead's 2024 guidance and a high-level overview of the business. And perhaps you could elaborate on some of the assumptions behind the 5% year-over-year product sales growth,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot